Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men

被引:62
作者
Taylor, S [1 ]
van Heeswijk, RPG
Hoetelmans, RMW
Workman, J
Drake, SM
White, DJ
Pillay, D
机构
[1] Univ Birmingham, Div Immun & Infect, PHLS Antiviral Susceptibil Ref Unit, Sch Med, Birmingham B15 2TT, W Midlands, England
[2] Birmingham Heartlands Hosp, Dept Sexual Med, Birmingham B9 5ST, W Midlands, England
[3] Slotervaart Hosp, Dept Pharm & Pharmacol, Amsterdam, Netherlands
关键词
HIV-1; lamivudine; nevirapine; pharmacokinetics; semen; stavudine;
D O I
10.1097/00002030-200009080-00014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine the concentrations of nevirapine (NVP),lamivudine (3TC) and stavudine (D4T) in seminal and blood plasma in HIV-l-infected men. Methods: Twelve HIV-1-infected men on NVP-containing regimens including 3TC (n = 8) or D4T (n = 11) provided 23 blood plasma and 22 seminal plasma samples for drug concentration and viral load quantitation. Concentrations of all drugs were assessed by sensitive validated high performance liquid chromatography (HPLC) assays. Blood plasma and seminal plasma viral loads were measured using nucleic acid sequence-based amplification (NASBA). Samples were grouped according to time after drug ingestion, 0-2, 2-4, 4-8 and 8-12 h. For matched seminal and blood plasma samples, obtained within 1 h of each other, a seminal : blood plasma ratio was calculated. Results: The concentration of NVP in seminal plasma appeared to mirror the concentrations in blood plasma. Absolute median seminal plasma NVP concentrations at 0-2, 2-4, 4-8 and 8-12 h were 3.1 mu g/ml (range 1.7-4.89), 2.68 mu g/ml (2.5-3.9), 2.5 mu g/ml (2.3-2.7) and 3.09 mu g/ml (1.3-9.1) The median seminal:blood plasma ratios for the four time periods were 0.54 (range 0.34-0.85), 0.83 (range 0.43-1.08), 0.53 (0.38-0.59), and 0.61 (0.59-0.78). 3TC and D4T appeared to reach concentrations in seminal plasma of a similar magnitude or higher than concentrations in blood plasma. The median seminal plasma viral load for all patients was less than 800 copies/ml (range <800-11 000). The median blood plasma viral load was less than 400 copies/ml (< 400-1100). Conclusion: NVP reaches concentrations in the semen approximately 60% of those in the blood plasma throughout the 12 h dosing period. In a smaller dataset 3TC and D4T concentrations in blood plasma and seminal plasma were similar. These data may well have implications for the evolution of drug-resistant virus within the genital (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:1979 / 1984
页数:6
相关论文
共 23 条
[1]   Poor reduction of HIV-1 RNA titres in nucleoside reverse transcriptase inhibitor experienced patients treated with indinavir combination therapy [J].
Ball, JK ;
Rowe, T ;
Curran, R ;
Irving, WL ;
Beards, GM ;
Sontag, G ;
Youle, M ;
Moyle, G ;
Pillay, D .
SEXUALLY TRANSMITTED INFECTIONS, 1999, 75 (05) :337-339
[2]   The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites [J].
Barry, MG ;
Khoo, SH ;
Veal, GJ ;
Hoggard, PG ;
Gibbons, SE ;
Wilkins, EGL ;
Williams, O ;
Breckenridge, AM ;
Back, DJ .
AIDS, 1996, 10 (12) :1361-1367
[3]   Analysis of human immunodeficiency virus in semen: indications of a genetically distinct virus reservoir [J].
Byrn, RA ;
Kiessling, AA .
JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 1998, 41 (1-2) :161-176
[4]   Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission [J].
Eron, JJ ;
Vernazza, PL ;
Johnston, DM ;
Seillier-Moiseiwitsch, S ;
Alcorn, TM ;
Fiscus, SA ;
Cohen, MS .
AIDS, 1998, 12 (15) :F181-F189
[5]   Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine [J].
Foudraine, NA ;
Hoetelmans, RMW ;
Lange, JMA ;
de Wolf, F ;
van Benthem, BHB ;
Mass, JJ ;
Keet, IPM ;
Portegies, P .
LANCET, 1998, 351 (9115) :1547-1551
[6]  
Gisolf EH, 1998, AIDS, V12, pS8
[7]   High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors [J].
Gupta, P ;
Mellors, J ;
Kingsley, L ;
Riddler, S ;
Singh, MK ;
Schreiber, S ;
Cronin, M ;
Rinaldo, CR .
JOURNAL OF VIROLOGY, 1997, 71 (08) :6271-6275
[8]   HIGH-DOSE NEVIRAPINE - SAFETY, PHARMACOKINETICS, AND ANTIVIRAL EFFECT IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
HAVLIR, D ;
CHEESEMAN, SH ;
MCLAUGHLIN, M ;
MURPHY, R ;
ERICE, A ;
SPECTOR, SA ;
GREENOUGH, TC ;
SULLIVAN, JL ;
HALL, D ;
MYERS, M ;
LAMSON, M ;
RICHMAN, DD .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (03) :537-545
[9]   Quantitative determination of (-)-2′-deoxy-3′-thiacytidine (lamivudine) in human plasma, saliva and cerebrospinal fluid by high-performance liquid chromatography with ultraviolet detection [J].
Hoetelmans, RMW ;
Profijt, M ;
Meenhorst, PL ;
Mulder, JW ;
Beijnen, JH .
JOURNAL OF CHROMATOGRAPHY B, 1998, 713 (02) :387-394
[10]   Antiretroviral-drug concentrations in semen: Implications for sexual transmission of human immunodeficiency virus type 1 [J].
Kashuba, ADM ;
Dyer, JR ;
Kramer, LM ;
Raasch, RH ;
Eron, JJ ;
Cohen, MS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1817-1826